Posts

Amgen Says Patient Health Data and IP Stolen in Cybersecurity Breach

Amgen disclosed a cybersecurity incident in which hackers stole patient health information and proprietary corporate data from cloud storage systems operated by third-party providers. The breach involved exfiltration of protected patient health information, proprietary data, and other sensitive information from multiple third-party cloud environments. Amgen has activated its cybersecurity response plan, contained the incident, and is investigating with third-party experts; it does not believe the incident will materially affect its financial condition or operations. The biotech company is evaluating legal and regulatory notification requirements and will notify affected patients as required, though no specific patient count or timeline for notification has yet been disclosed. Sources: Amgen discloses data breach involving patient health ... Amgen says cloud data breach exposed patient health ... Amgen discloses data breach, says patient information was ... Amgen Reports...

Novartis' Pluvicto leaps ahead into earlier manifestation of prostate cancer

Editors Corner: Why an AstraZeneca-Bristol Myers Squibb merger is a bad idea summarized and explained

Supernus, Indivior merge to create CNS-focused company and expand BD opportunities

CMS Locks in 2.3% Inpatient Hospital Base Pay Increase, Nudges Back CJR-X Model Start Date

Building the Intelligence Engine for Drug Discovery R&D Teams: Recent Developments in AI‑Driven Platforms and Workflows

Moderna delays norovirus vaccine trial readout because of too few infections

Skyrizi defies J&J rival Icatide as AbbVie raises full‑year 2026 guidance

AstraZeneca and Bristol Myers Squibb in $400 Billion Merger Talks

Leads Biolabs' PD-L1/4-1BB Bispecific Antibody IND Application for Combination Therapy in Metastatic Colorectal Cancer Approved, Strengthening GI Oncology Franchise

KOL Bulletin - FDA Approves Revtorpyk for HR+ / HER2– Metastatic Breast Cancer, but Logistical Hurdles May Restrict Uptake

FDA Committee Rejects Capricor's Duchenne Cell Therapy Amid Statistical Dispute

Apnimed secures $192M upsized IPO to launch sleep apnea pill Oxnimbi